Display options
Cite
Crose LE, Linardic CM. Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma. Sarcoma. 2011;2011:756982doi: 10.1155/2011/756982.
Crose, L. E., & Linardic, C. M. (2011). Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma. Sarcoma, 2011756982. https://doi.org/10.1155/2011/756982
Crose, Lisa E S, and Linardic, Corinne M. "Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma." Sarcoma vol. 2011 (2011): 756982. doi: https://doi.org/10.1155/2011/756982
Crose LE, Linardic CM. Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma. Sarcoma. 2011;2011:756982. doi: 10.1155/2011/756982. Epub 2011 Jan 02. PMID: 21253475; PMCID: PMC3022188.
Copy Download .nbib Format: NLM
Share it on

Sarcoma. 2011;2011:756982. doi: 10.1155/2011/756982. Epub 2011 Jan 02.

Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma.

Sarcoma

Lisa E S Crose, Corinne M Linardic

Affiliations

  1. Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA.

PMID: 21253475 PMCID: PMC3022188 DOI: 10.1155/2011/756982

Abstract

Rhabdomyosarcomas (RMSs) are the most common soft tissue sarcomas of childhood and adolescence. To date, there are no effective treatments that target the genetic abnormalities in RMS, and current treatment options for high-risk groups are not adequate. Over the past two decades, research into the molecular mechanisms of RMS has identified key genes and signaling pathways involved in disease pathogenesis. In these studies, members of the receptor tyrosine kinase (RTK) family of cell surface receptors have been characterized as druggable targets for RMS. Through small molecule inhibitors, ligand-neutralizing agents, and monoclonal receptor-blocking antibodies, RTK activity can be manipulated to block oncogenic properties associated with RMS. Herein, we review the members of the RTK family that are implicated in RMS tumorigenesis and discuss both the problems and promise of targeting RTKs in RMS.

References

  1. Am J Pathol. 2003 Oct;163(4):1417-28 - PubMed
  2. Anticancer Drugs. 2007 Nov;18(10):1173-81 - PubMed
  3. J Cell Biol. 2004 Jul 19;166(2):213-23 - PubMed
  4. Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8318-23 - PubMed
  5. Genes Chromosomes Cancer. 2010 Mar;49(3):224-36 - PubMed
  6. J Cell Biol. 1990 Oct;111(4):1623-9 - PubMed
  7. Cancer Res. 2009 May 1;69(9):3937-46 - PubMed
  8. Mol Cancer Ther. 2007 May;6(5):1620-8 - PubMed
  9. Cancer Res. 1991 Oct 15;51(20):5626-31 - PubMed
  10. Hum Mol Genet. 1994 Jul;3(7):1117-21 - PubMed
  11. Arch Dis Child. 2003 Apr;88(4):354-7 - PubMed
  12. Cancer Res. 1994 Nov 1;54(21):5531-4 - PubMed
  13. Cancer Res. 2005 May 1;65(9):3868-76 - PubMed
  14. J Clin Oncol. 2006 Feb 10;24(5):816-22 - PubMed
  15. Cancer Res. 2004 Nov 15;64(22):8428-34 - PubMed
  16. J Biol Chem. 2006 Jan 6;281(1):429-38 - PubMed
  17. J Clin Invest. 2009 Aug;119(8):2366-78 - PubMed
  18. Int J Cancer. 1998 Apr 13;76(2):223-7 - PubMed
  19. Br J Cancer. 2003 Jul 21;89(2):327-32 - PubMed
  20. Nature. 1995 Aug 31;376(6543):768-71 - PubMed
  21. Genes Dev. 2003 Dec 1;17(23):2950-65 - PubMed
  22. Clin Cancer Res. 2008 Jul 1;14(13):4119-27 - PubMed
  23. Nat Rev Mol Cell Biol. 2010 Mar;11(3):220-8 - PubMed
  24. Histopathology. 2009 Jun;54(7):873-9 - PubMed
  25. Pediatr Blood Cancer. 2008 Mar;50(3):581-7 - PubMed
  26. Cancer Res. 2009 Oct 1;69(19):7662-71 - PubMed
  27. J Biol Chem. 2009 Oct 23;284(43):29596-604 - PubMed
  28. Braz Dent J. 2010 Jan;21(1):68-73 - PubMed
  29. Nat Med. 2001 Jun;7(6):673-9 - PubMed
  30. Oncogene. 2008 Nov 20;27(51):6550-60 - PubMed
  31. Mol Cancer. 2010 Apr 12;9:75 - PubMed
  32. Mol Cell Biol. 1998 Jul;18(7):4118-30 - PubMed
  33. Br J Cancer. 1995 Nov;72(5):1224-9 - PubMed
  34. Oncogene. 1996 Apr 18;12(8):1697-705 - PubMed
  35. Oncogene. 2007 Mar 22;26(13):1932-40 - PubMed
  36. Pediatr Blood Cancer. 2010 Jul 1;54(7):921-6 - PubMed
  37. Br J Cancer. 2009 Dec 15;101(12):2030-7 - PubMed
  38. Cancer Res. 2003 Aug 15;63(16):5073-83 - PubMed
  39. Oncogene. 2008 Jun 26;27(28):3923-34 - PubMed
  40. Cancer Res. 2008 May 1;68(9):3077-80; discussion 3080 - PubMed
  41. Mod Pathol. 2006 Sep;19(9):1213-20 - PubMed
  42. Int J Dev Biol. 1997 Aug;41(4):597-605 - PubMed
  43. Int J Cancer. 2007 Mar 1;120(5):1141-9 - PubMed
  44. Birth Defects Res C Embryo Today. 2003 Nov;69(4):257-71 - PubMed
  45. Clin Cancer Res. 2005 Nov 15;11(22):8145-57 - PubMed
  46. Cancer. 2009 Sep 15;115(18):4218-26 - PubMed
  47. Nature. 1985 Sep 19-25;317(6034):260-2 - PubMed
  48. Cancer Res. 2008 Oct 1;68(19):8039-48 - PubMed
  49. Development. 1994 Mar;120(3):603-12 - PubMed
  50. Pediatr Blood Cancer. 2010 Dec 1;55(6):1126-33 - PubMed
  51. Cell. 1993 Oct 8;75(1):59-72 - PubMed
  52. FEBS Lett. 1999 Oct 1;459(1):100-4 - PubMed
  53. Clin Cancer Res. 2004 Oct 1;10(19):6750-8 - PubMed
  54. J Clin Oncol. 2008 Oct 20;26(30):4921-7 - PubMed
  55. Mol Cancer Ther. 2009 Dec;8(12):3341-9 - PubMed
  56. Endocr Relat Cancer. 2004 Dec;11(4):689-708 - PubMed
  57. J Cell Biol. 2006 Aug 28;174(5):677-87 - PubMed
  58. Genes Chromosomes Cancer. 2007 Nov;46(11):1028-38 - PubMed
  59. J Immunother. 2010 Apr;33(3):279-86 - PubMed
  60. Endocr Rev. 1996 Oct;17(5):481-517 - PubMed
  61. J Clin Oncol. 2002 Jun 1;20(11):2672-9 - PubMed
  62. Cancer. 2007 Nov 15;110(10):2293-303 - PubMed
  63. Genomics. 2002 Mar;79(3):278-84 - PubMed
  64. J Clin Oncol. 2010 Mar 1;28(7):1240-6 - PubMed
  65. Cancer Res. 2000 Nov 15;60(22):6253-8 - PubMed
  66. Cancer Res. 2003 Nov 15;63(22):7926-35 - PubMed
  67. Cancer Res. 1998 Aug 15;58(16):3542-6 - PubMed
  68. J Clin Invest. 1994 Jul;94(1):445-8 - PubMed
  69. Cancer Invest. 2006 Apr-May;24(3):310-7 - PubMed
  70. Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4213-8 - PubMed
  71. Proc Natl Acad Sci U S A. 1987 Feb;84(3):842-6 - PubMed
  72. Nat Med. 2002 Nov;8(11):1276-80 - PubMed
  73. J Clin Oncol. 2010 May 1;28(13):2151-8 - PubMed
  74. Exp Cell Res. 1996 Apr 10;224(1):143-51 - PubMed
  75. Cancer Res. 2006 May 1;66(9):4742-9 - PubMed
  76. Int J Cancer. 2000 Jul 1;87(1):29-36 - PubMed
  77. Development. 2002 Oct;129(19):4559-69 - PubMed
  78. Oncogene. 2005 Dec 1;24(54):8025-37 - PubMed
  79. J Clin Invest. 1994 Sep;94(3):1235-42 - PubMed
  80. Cancer Res. 2010 Aug 15;70(16):6497-508 - PubMed
  81. Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11393-8 - PubMed
  82. Cancer Res. 2000 Sep 15;60(18):5117-24 - PubMed
  83. Cell. 2000 Jan 7;100(1):57-70 - PubMed
  84. Cytokine Growth Factor Rev. 2005 Apr;16(2):139-49 - PubMed
  85. Cancer Res. 1994 Feb 15;54(4):903-7 - PubMed
  86. Genes Dev. 2004 Nov 1;18(21):2614-26 - PubMed
  87. N Engl J Med. 2004 May 20;350(21):2129-39 - PubMed
  88. J Cell Biol. 1997 Jun 2;137(5):1057-68 - PubMed
  89. J Clin Invest. 2009 Nov;119(11):3395-407 - PubMed
  90. J Clin Oncol. 2009 Jul 1;27(19):3148-53 - PubMed
  91. Cancer Res. 2003 Jun 1;63(11):2728-32 - PubMed
  92. Biochim Biophys Acta. 1998 Mar 12;1402(1):39-51 - PubMed
  93. Nature. 2000 Sep 14;407(6801):249-57 - PubMed
  94. Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):701-6 - PubMed
  95. Cancer Res. 1999 Feb 15;59(4):886-94 - PubMed
  96. Folia Histochem Cytobiol. 2009 Jan;47(3):485-9 - PubMed
  97. Cancer Res. 1996 Sep 1;56(17):3898-901 - PubMed
  98. Cell Mol Life Sci. 2003 Dec;60(12):2721-35 - PubMed
  99. Cancer Gene Ther. 2008 Jul;15(7):413-48 - PubMed
  100. Cell Growth Differ. 1990 Jul;1(7):325-31 - PubMed
  101. Mod Pathol. 2001 May;14(5):506-14 - PubMed
  102. Genes Chromosomes Cancer. 2007 Apr;46(4):348-58 - PubMed
  103. Genes Dev. 2008 May 15;22(10):1276-312 - PubMed
  104. Cancer Res. 2009 Jan 1;69(1):161-70 - PubMed
  105. Pediatr Blood Cancer. 2006 Mar;46(3):329-38 - PubMed

Publication Types

Grant support